Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by Ashgan M. Hessain
Total Records ( 2 ) for Ashgan M. Hessain
  Ihab M. Moussa , Ashgan M. Hessain , Abdullah A. Al- Arfaj , Khalid M. Farouk and Salah A. Selim
  Naja haje arabica (Arabian cobra) is the major cause of snake-bite mortality in Kingdom of Saudi Arabia. The treatments of the snake bite envenomation occur by anti-snake venom produced in horses previously immunized with a mixture of venom. Therefore, one of the main objectives of the current study is to produce anti Naja haje arabica immunoglobulin in high titer from the yolk of chickens by immunization of two groups of white leghorn chickens (24 weeks old) with 30 μg of Naja haje arabica emulsified in Freund’s Complete Adjuvant. Chickens has been immunized with booster doses of increasing concentrations of venom at two weeks’ time intervals to increase the antivenom titer in the egg yolk. The characteristic IgY band of 180 kDa was observed on SDS-PAGE of the final extracted product. The ELISA antibody values reached the plateau at 2nd weeks following 4th booster dose and remained significantly high up to the end of observation period. The measured antibody titers showed significant increase following the first, second, third booster doses. However, there were no differences between the third and the fourth booster doses. Western blot technique was used to evaluate the specificity of antivenom IgY antibodies. The LD50 of the Naja haje arabica venom has been found to be 0.4 mg kg–1 body weight of white Swiss mice and 100% protection against 40 LD50 of Naja haje arabica venom could be obtained by15 mg mL–1 anti Naja haje Arabica specific IgY. The neutralizing power of the anti Naja haje arabica venom IgY and the absence of pyrogen, bacterial and fungal contaminations or toxic products, encourage the use of egg yolk as a cheap source of anti-venom polyclonal antibodies.
  Moussa I. Mohamed , Khalid S. Al- Maary , Turki M. Dawoud , Ayman S. Mubarak , Ashgan M. Hessain and Kh. F. Mohamed
  Background: Infectious Bursal Disease (IBD) is a highly contagious disease characterize by severe damage of the bursa of fabricious and immuuosupperssion. The current study is aimed to evaluate the protective efficiency of IBDV specific IgY-antibodies prepared against the disease. Materials and Methods: Twenty white Leghorn laying hens were immunized with Infectious Bursal Disease Virus (IBDV) vaccine. Blood samples and eggs were collected simultaneously from laying hens before immunization and every 2 weeks after primary immunization. The collected eggs were used for separation of the yolk and extraction of IgY-antibodies by ammonium sulphate-caprylic acid method. Results: The mean log10 antibody titer of the serum samples showed significant increase after 2 weeks of immunization and reached its maximum level after 6-8 weeks from the primary immunization. Egg yolk IgY-antibodies level increased after 4 weeks of immunization and reached its maximum level after 8-10 weeks of immunization. Evaluation of the protective value of IBDV-specific lgY-antibodies revealed reduction in morbidity and mortality rate in challenged chickens 15 and 10%, respectively as compared with 90% morbidity and 40% mortality in non-immunized challenged chickens. In chicken group actively immunized with IBDV vaccine (live and inactivated), the morbidity and mortality rates were reduced to 10 and 5%, respectively, following challenge with virulent IBDV. However, when IBDV specific IgY-antibodies were used simultaneously with IBDV vaccines the morbidity and mortality rates were reduced to zero. Conclusion: The IBDV specific IgY-antibodies can be used simultaneously with IBDV vaccines for controlling the disease as the morbidity and mortality rates can be reduced to zero.
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility